21-Sept-2026 19:52:26

SYMBIOTEC PHARMALAB DELIVERS STEADY PERFORMANCE FOR Q1FY27

• Consolidated revenues stood at ₹218.2 Cr vs ₹203.2 Cr (YOY). • Consolidated EBIDTA was ₹45.2 Cr vs ₹58.0 Cr (YOY). • Consolidated PAT stood at ₹14.1 Cr vs ₹29.9 Cr (YOY). • Impact: Steady performance in Q1FY27.

Symbiotec Pharmalab Ltd

← Back to feed